Platelet aggregation plays an important role in the pathogenesis in arterial thrombotic disorders. The binding of fibrinogen via the Arg-Gly-Asp (RGD) recognition sequence to the platelet glycoprotein Ilb/llla (GPllb/lUa) receptor is an essential step of platelet aggregation induced by various physiologic agonists, and RGD-containing peptides that bind to the GPllb/llla receptor inhibit thrombus formation in vivo. L-cysteine, N-(mercaptoacetyl)D-tyrosyl-L-arginylglycyl-~aspar-tyl-cyclic (1 + 5)-sulfide, 5-oxide (64120). a cyclic RGDcontaining synthetic pentapeptide, inhibits adenosine diphosphate (ADP)-induced platelet aggregation with 50% inhibition (ICw) at a concentration of 0.05 pg/mL in human plasma, 0.12 pg/mL in hamster plasma, and 11 pg/mL in rat plasma. Corresponding values for the linear tetrapeptide Arg-Gly-Asp-Phe (RGDF) were 7 and 100 pg/mL in human and hamster plasma. The antithrombotia effects of G4120 and RGDF were evaluated in a hamster model consisting of a LATELET-MEDIATED arterial thrombosis is a major P pathogenetic mechanism for coronary artery thrombosis and for reocclusion after successful thrombolytic therapy.'-5 Consequently, suppression of platelet aggregation might be useful for the prevention of arterial occlusion or reocclusion. Aspirin: prostaglandin El,' selective thromboxane (TX) Az synthase inhibitors?r9 TXA, receptor antagonists in combination with serotonin receptor antagonists,lOJ1 combined TXAz synthase and prostaglandin endoperoxide receptor blocking a g e n t~~J~J~ and selective thrombin inhibitors14-17 have been investigated as means to inhibit thrombus formation in experimental animal models. The binding of fibrinogen via the Arg-Gly-Asp (RGD) recognition sequence to the platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor is an essential step of human platelet aggregation induced by adenosine diphosphate (ADP), collagen, thrombin, epinephrine, etc.18J9 Therefore, GPIIb/ IIIa may constitute a specific target for antithrombotic therapy. The binding of fibrinogen to GPIIb/IIIa is inhibited by monoclonal antibodies to GPIIb/IIIa,m RGDcontaining peptides,21,22 and RGD-containing viper venom Antithrombotic effects of these GPIIb/ IIIa antagonists in vivo were established in d0gs.2~-~~ Recently, synthetic peptide derivatives with potent antithrombotic properties have been de~cribed?O-~~ but the in vivo properties of these agents remain to be further explored.
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The rat femoral vein platelet-mediated mural thrombosis model, developed by Stockmans et a1,% allows the continuous quantitative monitoring of mural platelet-dependent thrombus formation. However, platelet aggregation in the rat is less sensitive to inhibition of the GPIIb/IIIa-mediated pathway.35 In the present study, we observed that the two RGD-containing peptides tested inhibit platelet aggregation in platelet-rich plasma of hamsters and humans with a comparable and much higher efficacy than in rat plasma, indicating that hamsters might be preferable to rats for the investigation of their antithrombotic effects. The effects of L-cysteine,N-(mercaptoacetyl)-D-tyrosyl-L-arginylglycyl-Lmural platelet-rich femoral vein thrombus induced by standardized endothelial cell damage. Bolus intravenous injection of G4120 was followed by a biphasic disappearance of G4120 from plasma with t 1 h of 3.7 minutes and t(/zfi of 63 minutes, corresponding to a plasma clearance of 5.2 2 0.68 mL/min. Bolus intravenous injection of G4120 inhibited ex vivo platelet aggregation with 0.5 pmol/L ADP and in vivo thrombus formation in a dose-dependent manner, with lDSo of 11 and 11 pg/kg, respectively. Bolus injection of RGDF inhibited in vivo thrombus formation; 43% inhibition was obtained at a dose of 30 mg/kg. Thus, this hamster plateletrich femoral vein thrombosis model may be useful for the investigation of the antithrombotic properties of platelet GPllb/ llla antagonistic peptides. The cyclic synthetic peptide G4120 appears to have a very potent antithrombotic activity in vivo. 0 1992 by The American Society of Hematology.
a-aspartyl-cyclic(1 + 5) sulfide, 5-oxide (G4120), a synthetic cyclic pentapeptide with a high affinity (kd, 4 nmol/L) to the GPIIb/IIIa receptor that binds rapidly and reversibly to platelet~,3~,~~ and of RGDF, a linear tetrapeptide with lower were studied in this hamster femoral vein platelet-mediated mural thrombosis model.
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IMURA ET AL aggregation was measured with a standard aggregometer (Chronolog Corporation, Havertown, PA) according to the method of Born?8 PRP (250 pL) was preincubated at 37°C for 2 minutes and then incubated for 2 minutes with G4120, RGDF, or solvent (0.9% NaCl), followed by stimulation with ADP or collagen. The concentration of ADP or collagen was chosen to obtain submaximal aggregation in each PRP.
Pharmacokinetics. The pharmacokinetic parameters describing the plasma disappearance of G4120 after bolus IV injection in hamsters were determined by measurement of the residual plasma concentrations of G4120 versus time. Plasma levels of G4120 were determined by immunoassay after extraction of G4120 from citrated plasma (performed at the Department of Analytical Chemistry, Genentech Inc). After IV bolus injection of 100 pg/kg G4120, blood samples were taken at 0.5,1,2,5,7,10,20,30,40,50, and 60 minutes. The mean results obtained in a group of three hamsters of plasma G4120 levels versus time expressed as a fraction of the first sample were plotted on a semilogarithmic scale and fitted with a sum of two exponential terms, C(t) = Ae-"' + Be-pt by graphical curve peeling.3g Therefore, the linear terminal portion of the G4120 versus the time curve was extrapolated to yield the ordinate intercept B, and this line had a slope -p. The extrapolated values were subtracted from the initial plasma values and these corrected values were fitted with a straight line with slope -a and intercept A.
The clearance parameters were calculated from the coefficients (A and B) and the exponents (a and p) describing the disposition of G4120 from plasma using the standard formula derived by Gibaldi and P e~~i e r .~~ The volume of the central compartment Male hamsters with a body weight 95 to 140 g were anesthetized with pentobarbital (50 mg/kg, IP) and premedicated with atropin (1.25 mglkg, IP). After shaving the neck, the groins, and the left medial upper leg, longitudinal incisions were made at the neck and from the left lower abdomen down to the knee region. The left jugular vein was exposed and cannulated for administration of drugs and of an additional 25 mg/kg pentobarbital injection just before thrombus induction. The epigastric artery and vein were exposed and coagulated.
The femoral vein was exposed from the inguinal ligament to the knee and mounted on the transilluminator developed by Stockmans et Mural thrombosis was triggered by vessel wall damage with the modified Acland vessel clamp (#ST-RD-S; S and T Microlab AG, Neuhausen am Rheinfall, Switzerland) mounted on a micromanipulator. The clamp was mounted above the vessel and aligned parallel to the long axis of the femoral vein. The adventitia of the vein was grasped with a microsurgical forceps and the anterior wall of the vein was compressed between the jaws of the trauma clamp that compressed the vessel with a pressure of 1.5 kg/mm2. Once the vein was properly positioned in the clamp, the movable tip was rotated three times through 360" (90" clockwise, 180" counterclockwise, and again 90" clockwise). In this way, the two endothelial surfaces of the vein were rubbed against each other. The trauma clamp was applied to the vessel for about 30 seconds. This resulted in the development of two platelet-mediated mural thrombi at the sites of trauma, which were visualized by increased light transmittance through the transilluminated blood vessel segment. Routinely, the thrombus formed at the site compressed by the fixed jaw of the trauma clamp was used for analysis.
Hamster platelet-rich femoral vein thrombosis model.
Thrombus formation was continuously monitored over 30 to 40 minutes under a Zeiss OPMI-1 (Carl Zeiss, Oberkochen, Germany) operating microscope at x30 magnification, with videotape recording, using a beam splitter, a black and white video camera (RCA CCD TC104X) (Burle Industries, Lancaster, PA), and a VHS video-recorder (Panasonic NV G21hQ) (Matsushita Electric Trading Co, Osaka, Japan). The change over time of the light transmission through the blood vessel at the site of trauma was continuously recorded with the video system. During the first 3 minutes after trauma clamp release, readjustments in focus and position were made to establish optimal image recording. Both femoral veins were used in each experiment and were subjected to the same procedure; firstly to establish a control value in the absence of test substance and secondly to quantitate a drug effect. The dissection of the right femoral vein was begun after the procedure on the left femoral vein was completed. The antithrombotic agents or solvent were administered as a bolus injection via the jugular vein cannula 5 minutes before the induction of the second trauma.
All animal experiments were performed according the guidelines of the International Society of Thrombosis and Haemostasis. 40 The videotape of the experiment was analyzed off line, using a dedicated automated image analysis system (Max Vision AT1; Datacube Inc, Peabody MA). Frames at 10 seconds distance were digitized on a 512 x 512 pixel matrix, with a resolution of 256 grey values. Each experiment was analyzed separately in the following way. First, the tape was viewed in fast forward replay, and a frame with maximal thrombus size was visually selected. The frame was digitized and an elliptic region was delineated that overlayed the thrombus and, in addition, about 20% of the surrounding area (thrombus zone [TZ]). Around this TZ, a second concentric ellipse was delineated and the region between these two ellipses was used as a reference zone (RZ). These two ellipses were stored in an overlay screen and were used for evaluation of all the digitized frames of the experiment. The area of the TZ and R Z (in number of pixels, NTZ and NRZ) and their respective mean intensity (average pixel grey value, XTZ and XRZ) were determined. If there were differences in mean intensity between the T Z and R Z in the absence of a thrombus, the XRZ values were corrected for the difference (A) between XRZ and XTZ as determined from the last 10 frames (last 100 seconds) of the experiment. To correct for variability in recorded light intensity due to differences in vessel size or light absorption by the vessel wall, the mean thrombus intensity NTZ X (XTZ -[XRZ + A]) was normalized to the corrected mean intensity of the RZ. Thus, the total thrombus light intensity (T) was expressed in arbitrary units (AU) using to the following formula:
The total area of the light intensity versus time curve was determined and the drug effect was calculated from the AUC in the second experiment, expressed as a percentage of the AUC in the first experiment. One, 10, 20, and 40 minutes after the administration via the jugdar vein cannula of 1, 10, or 100 pg/kg G4120 or of 0.9% NaCl (in a totalvolume of 1 mL/kg), blood was collected in 3.15% sodium citrate (0.1 mL for 0.9 mL of blood) by puncture of the exposed abdominal aorta in anesthetized hamsters (50 mg/kg pentobarbital IP). The blood sample was centrifuged at 950 rpm for 10 minutes and 2,000 rpm for 10 minutes at room temperature to obtain PRP and PPP, respectively. The platelet count of the PRP was adjusted to 200,000 platelets/pL Platelet aggregation studies ex vivo.
For 
RESULTS
Inhibitory effect of G4120 on platelet aggregation in hamster, rat, dog, and human PRP in vitro. To select a suitable animal model for the examination of the antithrombotic properties of G4120 and RGDF in vivo, their inhibitory potency on ADP-and collagen-induced platelet aggregation was measured using PRP from hamsters, rats, dogs, and humans. G4120 inhibited ADP-and collagen-induced platelet aggregation in all species in a wncentrationdependent manner (Fig 1) . IC50values of G4120 in hamster and human platelet aggregation ( Fig 1A) were 0.12 and 0.05 pg/mL, respectively, for ADP-induced aggregation, and 0.13 and 0.11 pg/mL, respectively, for wllageninduced aggregation (Fig 1B) . In the dog system, G4120 inhibited ADP-and collagen-induced aggregation with IC5, values of 0.02 and 0.06 pg/mL, respectively, whereas in the rat species IC5, values were 11 and 12 pg/mL, respectively (Fig 1A and B) . RGDF inhibited aggregation of hamster and human platelets with IC50 values of 100 and 7 pg/mL, respectively, for ADP-induced aggregation and with IC,, values of 30 and 18 p.g/mL, respectively, for wllageninduced aggregation (Fig 2) .
When G4120 was injected as a single bolus of 100 pg/kg in three hamsters, a plasma concentration of 0.42 k 0.04 pg/mL was reached. The disappearance rate of G4120 could be described by a sum of two exponential terms (Fig 3) . The pharmacokinetic parameters, derived from the plasma disappearance rate as described in Materials and Methods, are summarized in Table 1 . G4120 disappears from plasma in a biphasic mode with tl/a = 3.7 +-0.7 minutes and tl/p = 63 k 4 minutes, corresponding to a clearance of 5.2 & 0.68 mL/min. Antithrombotic effects of G4120 and RGDF in the hamster femoral vein thrombosis model. Figure 4 illustrates typical light transmission versus time curves of the thrombus areas in the left (first thrombus) and right (second thrombus) femoral veins, as obtained in individual hamsters. M e r clamp release, the mural thrombus initially grows, producing an increase in light transmission, it reaches a maximum volume after 10 to 15 minutes, it occasionally embolizes partially, resulting in a transient reduction of light transmission, and, finally, it disappears within approximately 40 minutes. In seven control experiments without drug administration, the total area under the light transmission versus time curves of first thrombi produced in the left femoral vein was 152,000 f 33,000 AU and the total AUC of second thrombi produced in the right femoral vein was 153,000 2 54,000 (mean f SEM) (P = NS). G4120 (3 to 100 pg/kg) inhibited thrombus formation in a dose-dependent manner, as illustrated in Fig 5, with an IDso of 11 pg/kg. RGDF (10 and 30 mg/kg) also inhibited in vitro thrombus formation, 38% k 17% (n = 4) and 43% +-20% (n = 4), respectively. Inhibitory effect of G4120 in ex vivo platelet aggregation in hamsters. ADP, at a concentration of 0.5 or 1 pmol/L, induced platelet aggregation in PRP obtained from hamsters administered 0.9% NaCl, resulting in a change in transmittance of 50% 4 15% (n = 4) and 73% f 8% (n : 4), respectively. In hamsters administed a bolus injection of 1, 10, or 100 pg/kg G4120, the change in transmittance was reduced in a dose-related manner, as illustrated in Fig 6. Forty minutes after bolus injection of 10 pg/kg G4120, platelet aggregation was nearly restored, whereas at a dose of 100 pg/kg, significant residual inhibition persisted. The platelet counts 10 minutes after the administration of 0.9% NaCl, and 1, 10, and 100 pg/kg G4120 were 28 f 1.8 (n = 4), 33 f 2.3 (n = 3), 31 & 0.3, and 29 f 1.8 x 10,000 platelets/ pL, respectively.
Pharmacokinetics of G4120 in hamsters.

DISCUSSION
The fibrinogen molecule contains the RGD recognition sequence that interacts with the GPIIb/IIIa receptor on the platelet membrane.21-25 Synthetic RGD-containing peptides that bind to GPIIb/IIIa inhibit platelet aggregation induced by various physiologic stimuli, including ADP, collagen, thrombin, and epinephrine, in vitro2*-z and inhibit thrombus formation in vivo.28,30,31 In the present study, we have examined the antithrombotic effect of a novel synthetic cyclic RGD-containing pentapeptide, G4120, in a hamster platelet-rich femoral vein thrombosis model. G4120 was found to inhibit ADP-and collagen-induced platelet aggregation in hamster, human, and dog PRP with IC50 values in the range of 0.02 to 0.13 pg/mL, whereas the linear tetrapeptide RGDF had ICs, values in the range of 10 to 100 pg/mL. The ICs0 values for inhibition of ADPstimulated aggregation were lower than previously re- ported: 0.1 and 0.15 pg/mL for human and dog PRP, with 17 and 30 pmol/L ADP, re~pectively.~~ This is probably due to the use of a submaximal ADP concentration in these studies. The ICso values for inhibition of the collagenstimulated aggregation of human PRP were consistent with the values previously reported, 0.13 and 0.17 pg/mL, for stimulation with 2 and 17 pg/mL collagen.33 G4120 was about 100 times less inhibitory towards ADP-or collageninduced aggregation of rat PRP. This relative resistance of rat platelets towards inhibition with RGD-containing peptides has previously been rep0rted.~5 Because of the similar reactivity towards G4120 of hamster platelets and the different reactivity of rat platelets, as compared with the human system, the hamster was selected as a preferred small animal species for the evaluation of the antithrombotic effect of RGD-containing peptides.
Our laboratory has previously reported a new plateletmediated thrombosis model in the femoral vein in the rat, emboli~ation.3~ In the present study, this technique was applied to the hamster. As in the rat femoral vein thrombosis model, the reproducibility of the area under the light transmittance versus time curves of the thrombus region in the hamster model was acceptable because similar values were obtained when the procedure was sequentially applied on both femoral veins in the same animal. Therefore, the hamster femoral vein thrombosis model allows the use of both femoral veins, the first one to establish a control value in the absence of test substance and the second one to quantitate a drug effect as a percentage of the control value in an individual hamster.
After bolus injection of G4120, the compound disappeared with a terminal half-life (tl/p) of 63 minutes. Furthermore, significant inhibition of ex vivo platelet aggregation was observed 20 minutes after injection of 10 pg/kg and 40 minutes after injection of 100 pg/kg. Thus, for convenience, the compound was administered in the present study by bolus injection.
G4120 inhibited thrombus formation in the hamster platelet-rich femoral vein thrombosis with an IDso of 11 kg/kg, which corresponded with the IDso for the inhibition of ex vivo platelet aggregation with ADP with no significant effect on platelet count. The linear tetrapeptide RGDF also inhibited the in vivo thrombus formation in a dosedependent manner, with an IDso of approximately 30 mg/kg. These results suggest a direct relationship between binding of G4120 and RGDF to the GPIIb/IIIa receptor, inhibition of platelet aggregation, and inhibition of in vivo thrombus formation.
Because of marked interspecies differences in the inhibitory effects of GPIIb/IIIa antagonists on platelet aggregat i~n~~ and because of the poor reactivity of rats and rabbits, most in vivo experiments to investigate the antithrombotic effects of GPIIb/IIIa antagonists have been performed in dogs.26-29 The hamster platelet-rich femoral vein thrombosis model used in the present study shows that this small animal species reacts to RGD-containing peptides in a way similar to humans. Therefore, this model might facilitate the development of GPIIb/IIIa antagonists. Three types of GPIIb/IIIa antagonists have been developed: murine monoclonal antibodies to GPIIb/IIIa, RGD-containing snake venom peptides, and synthetic RGD-containing small molecular peptide^.^-^^ F(ab')z fragments of a murine monoclonal antibody, 7E3, inhibit thrombus formation in a canine coronary artery thrombosis accelerate thrombolysis with recombinant tissue-type plasminogen activator (rt-PA), and prevent reocclusion in a canine coronary thrombosis Snake venom peptides also have been shown to inhibit platelet aggregation strong-1~. For personal use only. on August 30, 2017. by guest www.bloodjournal.org From the venom of the malayan pit viper Agkistrodon rhodostoma, enhanced thrombolysis with rt-PA and prevented reoccl~sion.~~ These agents have potent antithrombotic effects, but their clinical usefulness might be limited by the lack of oral activity or the risk of immunogenicity and variable effects on platelet number. RGD-containing small peptides might overcome some of these disadvantages. Very recently, some synthetic peptide derivatives with a high affinity for the GPIIb/IIIa receptor have been de~c r i b e d .~~"~ One of these peptides, G4120, appears to have a potent antithrombotic potency in vivo and may offer promise for antithrombotic therapy.
In conclusion, the hamster platelet-rich femoral vein thrombosis model with quantitation by transillumination is reproducible and useful for the investigation of the antithrombotic effects of platelet GPIIb/IIIa antagonistic peptides. A cyclic synthetic peptide, G4120, appears to have a potent antithrombotic activity in this model. 
